Medisyn Technologies

Mark Kroll, Ph.D., joins Medisyn's Board of Directors

Wayzata, MN – March 22, 2006

Andcor Companies, Inc., the venture catalyst for Minnesota's most promising emerging companies, and Medisyn Technologies, Inc., a drug development company, are pleased to announce Mark Kroll, Ph.D., widely recognized as one of the world's leading inventors of implantable medical devices, has joined the Medisyn board of directors.

Dr. Kroll is well-known within the worldwide medical device industry as a technology expert with deep knowledge of its applications in business development. By some estimates, 99 percent of implantable defibrillators incorporate at least one Kroll patent invention.

In discussing his reason for joining Medisyn's board, Dr. Kroll commented, "I was very impressed with the sheer elegance of the Medisyn approach. The technology has the potential to create a new framework for drug discovery that speeds up and expands the capabilities of current approaches."

According to Thomas Ingolia, Medisyn's CEO, "Dr. Kroll's expertise in our underlying technology brings Medisyn unparalleled value as we continue to commercialize our Forward Engineering&trade drug discovery platform. We are indebted to Andcor for identifying Dr. Kroll and advocating Dr. Kroll join our board.

Medisyn's Forward Engineering proprietary technology platform significantly increases the accuracy and speed with which new compounds are discovered. The company currently deploys Forward Engineering in both natural, non-prescription therapeutic and traditional pharmaceutical markets. Medisyn also works with both pharmaceutical and biotechnology companies to sharpen and streamline their discovery initiatives, primarily in cancer treatment. The company is engaged in a long-term collaborative research project with the University of Minnesota's Academic Health Center.

Dr. Kroll, until recently retired, was the senior vice president and chief technology officer for St. Jude Medical Inc., (NYSE:STJ) Cardiac Rhythm Management division. He began as vice president of the Tachycardia Business division and held various senior executive roles within St. Jude since 1995. He was awarded 'Fellow' recognition by the American College of Cardiology (FACC), and is co-author of 'Implantable Cardioverter Defibrillator Therapy'. He has been listed in 'Who's Who in Science and Engineering' since 1992. Dr. Kroll has authored over 75 papers, invited presentations, book chapters, and abstracts. With 202 issued US patents, he is the most prolific inventor in Minnesota. He is also a director of Haemonetics Corp. (NYSE:HAE) and Taser Intl. (NASD:TASR).

About Medisyn Technologies

Medisyn Technologies is a unique drug design and discovery company that uses proprietary technology to make drug discovery faster, more predictable and less expensive. Based on molecular topology, Medisyn's Forward Engineering platform enables the discovery and design of novel, diverse and unexpected compounds that meet exact parameters for a specific therapeutic use. By compressing design and discovery time from years to weeks and optimizing lead candidates, Medisyn's novel approach enables drug discovery customers to reduce risk, improve probability of success and control costs associated with the traditional lead discovery process. The company is initially focused on treating cancer and is currently completing pre-clinical validation of MT103, a promising lead candidate for non-small cell lung cancer. It has an additional 26 anti-cancer compounds in varying stages of development. For more information about Medisyn Technologies, visit the company's website at www.medisyntech.com.

About Andcor

Andcor Companies, Inc. is a leading provider of professional and executive level search services for emerging growth companies. As a leading resource for the assembly of entrepreneurial management teams, Andcor has developed an unparalleled relationship-driven network within the emerging growth community and leverages this unique and valuable resource to help its clients transform vision into reality.

Founded in 1969, Andcor has vast experience with pre-revenue through high growth small-cap clients in a broad array of industries and has established itself as a pioneer in the recruiting industry through its equity-for-services and staged payment fee structures, refundable retainer agreements, and use of combined networks. Additional information can be found at www.andcor.com.